Suggestions
Denis Azhgirevich
Managing Partner M&A at Nexus Capital
Denis Azhgirevich is an experienced M&A advisory professional currently serving as the Managing Partner M&A at Nexus Capital.1 He specializes in mergers and acquisitions with a primary focus on the Pharma, FMCG, Packaging, and IT sectors.1
Professional Background
Azhgirevich has a strong presence in the pharmaceutical and M&A industries. He regularly shares insights and updates about significant deals and industry trends. For instance, he reported on Eurofarma Laboratórios S.A.'s acquisition of Genfar S.A. from Sanofi for approximately 300 million.3
Contributions and Expertise
As part of his role, Azhgirevich publishes a Pharma M&A Newsletter, providing essential news and analysis in the Russian pharmaceutical industry. He has released editions covering various months, including September and November 2021.45 These newsletters likely offer valuable insights into the current state and future trends of pharmaceutical mergers and acquisitions in Russia.
Career Progression
Azhgirevich's LinkedIn profile indicates that he started his position as Managing Partner at Nexus Capital relatively recently. He has expressed enthusiasm about this new role in his professional journey.26
Through his work and online presence, Denis Azhgirevich demonstrates a deep understanding of the M&A landscape, particularly in the pharmaceutical sector, and continues to be an active voice in the industry.
Highlights
I’m happy to share that I’m starting a new position as Managing Partner at Nexus Capital!
Essential M&A News in World Pharma for April 2023 Cannabis producer Tilray to buy Hexo for $56 mln https://lnkd.in/egHih5V8 Merck to buy Prometheus Biosciences for about $11 billion https://lnkd.in/eVr3p9z2 Satsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSA https://lnkd.in/eqzCG8mC. Bankruptcy court approves Intas-Shamrock plan for Unimark Remedies https://lnkd.in/ebBDDZdj. GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health https://lnkd.in/ehTpS777 CHEPLAPHARM announces acquisition of Zyprexa® from Lilly https://lnkd.in/eXcA7SFJ. Indian pharma Ipca Labs to buy over 33% stake in Unichem https://lnkd.in/ewh7cJVM). Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio https://lnkd.in/eAyAzns5 Assertio picks up Spectrum and its approved drug Rolvedon in $248M-plus deal https://lnkd.in/e4btqPtb. Astellas Pharma buys Iveric Bio for $5.9 billion https://lnkd.in/egPvUK-h #april2023 #mergers #mergersandacquisitions #mergersacquisitionsdivestitures #investment #russia #russiasanctions #divestment #businessexit #multinationalcompanies
